KKR on verge of buying stake in India's Gland, sources say

After rumors ignited speculation last month, a KKR buyout of India's Gland Pharma may be on the way, according to Reuters' sources. The private equity firm will reportedly pay about $150 million for nearly 30% of the drugmaker, which makes heparin and some other products for the cardiovascular and orthopedic segments. For KKR, the deal would follow up on a string of recent healthcare investments. Last month, it agreed to buy a $1.67 billion stake in Panasonic's healthcare arm and sealed a deal to buy and merge PRA and ReSearch Pharmaceutical Services, creating the world's fourth-largest CRO in the process. Story | More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.